Decipher Labs Ltd

Standalone results

• Revenue from operations ₹581 lakhs; Total income ₹981 lakhs.
• Loss before tax ₹7.85 lakhs; loss after tax ₹7.93 lakhs.
• EPS (basic and diluted) ₹-0.17 each.
• Segment revenue: Manufacturing drugs ₹0.40 lakhs; Consultancy ₹541 lakhs; Total ₹981 lakhs.

Consolidated results

• Revenue from operations ₹241.39 lakhs; Total revenue ₹251.13 lakhs.
• Consolidated loss before tax ₹218.52 lakhs; after tax ₹218.57 lakhs.
• Total comprehensive income ₹-193.11 lakhs.
• Subsidiaries included: Decipher Software Solutions LLC (USA) and Decipher W.L.L Bahrain.

Notes & audit

• Audit Committee and Board reviewed / approved results on 13-Aug-2026.
• Labour Codes effective 21-Nov-2025; company estimates no liability for own employees.

Filing notes

• Meeting details (date/time/location) and agenda items are not disclosed in this filing chunk.

Dematerialisation processing and depository update

• Details of dematerialised securities for the quarter furnished to all exchanges where listed.
• Securities received for dematerialisation were mutilated and cancelled after verification; depositories updated as registered owner within 15 days.

Financial Performance 📊

• Standalone Q3 revenue: ₹13.20 lakhs; 9M revenue: ₹106.85 lakhs, up from ₹64.95 lakhs YoY.
• Standalone Q3 PAT: ₹1.67 lakhs; 9M PAT loss: ₹6.48 lakhs; EPS Q3: ₹0.01, 9M negative.
• Consolidated Q3 revenue: ₹321.26 lakhs; 9M revenue: ₹1,045.00 lakhs, down from ₹1,911.24 lakhs YoY.
• Consolidated Q3 PAT loss: ₹53.88 lakhs; 9M PAT loss: ₹308.54 lakhs; EPS Q3: -₹0.53, 9M: -₹3.08.
• Total standalone expenses 9M: ₹115.35 lakhs; consolidated expenses 9M: ₹1,443.37 lakhs.
• No exceptional items reported in standalone or consolidated results.

Segment Performance

• Standalone 9M revenue: Pharmaceutical manufacturing ₹7.50 lakhs, Consultancy ₹39.35 lakhs.
• Consolidated 9M revenue: Pharmaceutical manufacturing ₹67.50 lakhs, Consultancy ₹977.50 lakhs.
• Consolidated 9M segment PBT: Pharma loss ₹5.43 lakhs, Consultancy loss ₹85.23 lakhs.
• Consolidated 9M segment assets: Pharma ₹915.36 lakhs, Consultancy ₹1,345.70 lakhs.
• Consolidated 9M segment liabilities: Pharma ₹76.42 lakhs, Consultancy ₹292.75 lakhs.

Corporate & Compliance

• Paid-up equity share capital: ₹10.10 crores (₹10 per share).
• New Indian Labour Codes effective Nov 21, 2025; no estimated liability for own employees.
• Consolidated results include Decipher Software Solutions LLC (USA) and Decipher Soft Middle East W.L.L (Bahrain).
• Auditor's review reports issued with no material misstatements.
• Board and Audit Committee approved results on 12 Feb 2026.

Business Model & Segments

• Operates in pharmaceutical manufacturing and consultancy services segments.

Board Appointment

• Special resolution approved to appoint Mr. Dalavath Amar Singh as Director and Whole-Time Director.
• Resolution passed unanimously with 100% votes in favor (237,806 votes; 2.35% of total shares).
• Promoters/promoter group were not interested or participating in the resolution.

Meeting and Voting Details ️

• EGM held on February 12, 2026; record date for voting was February 5, 2026.
• Total shareholders on record: 30,080; 41 shareholders attended via video conferencing.
• Voting conducted via remote e-voting and e-voting at the EGM; scrutinizer certified fair voting.

Shareholding and Control

• No material changes to shareholding pattern or control reported from the director appointment.

Board Appointment

• EGM on 12.02.2026 approved the appointment of Mr. Dalavath Amarsingh as Whole-Time Director of Decipher Labs Limited.
• The appointment was passed by special resolution with 100% votes in favor (237,806 votes), no opposition or invalid votes.
• The resolution was not of interest to promoters or promoter group members.
• No changes to shareholding pattern or promoter control resulted from this appointment.
• No capital raising, related party transactions, or remuneration changes were disclosed in this EGM.

🗓️ Meeting Details

• Board meeting scheduled for Thursday, 12 February 2026 at the company's registered office.

📊 Financial Results

• Approval of unaudited standalone and consolidated financial results for quarter and nine months ended 31 December 2025.
• Consideration of Limited Review Report (standalone and consolidated) for quarter ended 31 December 2025.

Appointment of Director

• Mr. Dalavath Amar Singh appointed as Executive Director and Whole-Time Director for 2 years from 13 Nov 2025.
• Remuneration fixed at Rs. 6,00,000 per annum, adjustable within Schedule V limits.
• Board authorized to vary remuneration and pay in case of losses as per Schedule V.
• Mr. Singh holds no shares currently; no change in shareholding or control.
• No other directors or KMPs are interested in the resolution.
• Resolution recommended by Board and Nomination & Remuneration Committee; voting outcome not disclosed.

Financial Context

• Company reported turnover of Rs. 87.60 lakhs and net loss of Rs. 44.02 lakhs in FY 2024-25.
• Business expansion is ongoing.

Governance

• No other board or management changes reported.